Literature DB >> 21123112

Blood-pressure drugs and cancer: much ado about nothing?

Lars H Lindholm1, Bo Carlberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21123112     DOI： 10.1016/S1470-2045(10)70271-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies.

Authors:  Chan Yoon; Hyun-Sik Yang; Inpyo Jeon; Yoosoo Chang; Sang Min Park
Journal:  CMAJ       Date:  2011-08-29       Impact factor: 8.262

2.  Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.

Authors:  Matthew T Roe; Derek D Cyr; Debra Eckart; Phillip J Schulte; Michael A Morse; Kimberly L Blackwell; Neal E Ready; S Yousuf Zafar; Anne W Beaven; John H Strickler; Jane E Onken; Kenneth J Winters; Lisa Houterloot; Dmitry Zamoryakhin; Stephen D Wiviott; Harvey D White; Dorairaj Prabhakaran; Keith A A Fox; Paul W Armstrong; E Magnus Ohman
Journal:  Eur Heart J       Date:  2015-12-05       Impact factor: 29.983

3.  Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cancer risk: an updated meta-analysis of observational studies.

Authors:  Kayeong Shin; Jiwoo Yang; Yeuni Yu; Eunjeong Son; Kihun Kim; Yun Hak Kim
Journal:  Ther Adv Drug Saf       Date:  2022-10-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.